Abecma Suspension
NDC Package 59572-515-01
Package Information
Abecma (idecabtagene vicleucel) suspension is aBECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This formulation utilizes a suspension delivery system. Marketed by Celgene Corporation, this product is identified by NDC 59572-515 and is authorized under FDA application BLA125736.
Identification & Billing
- RxCUI: 2536434 - idecabtagene vicleucel 510,000,000 CELLS in 30 ML Injection
- RxCUI: 2536434 - 30 ML idecabtagene vicleucel 17000000 CELLS/ML Injection
- RxCUI: 2536434 - idecabtagene vicleucel 17000000 CELLS/ML per 30 ML Injection
- RxCUI: 2536434 - idecabtagene vicleucel 510,000,000 CELLS per 30 ML Injection
- RxCUI: 2536439 - Abecma 510,000,000 CELLS in 30 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59572 - Celgene Corporation
- 59572-515 - Abecma
- 59572-515-01 - 1 SUSPENSION in 1 BAG
- 59572-515 - Abecma
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (59572-515). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59572-515-01 identifies a specific commercial package of 1 suspension in 1 bag of Abecma, a cellular therapy labeled by Celgene Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This suspension is formulated for intravenous use and contains idecabtagene vicleucel as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Celgene Corporation on March 26, 2021. The current certification is valid through December 31, 2026.
How is this Celgene Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59572051501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
